Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Chronic kidney disease: assessment and management

NICE guideline
Reference number: NG203
Published: 25 August 2021
Last updated: 24 November 2021

History

Guidance published

Committee member list (PDF 137 KB)

Published:

25 August 2021
Consultation comments and responses (PDF 2.96 MB)

Published:

25 August 2021
Equality impact assessment 4 (PDF 112 KB)

Published:

25 August 2021

Stakeholder list updated

Stakeholder list (PDF 202 KB)

Published:

24 August 2021

Declaration of interests

Register of interests (PDF 719 KB)

Published:

24 August 2021

Draft guidance consultation

Draft guidance consultation
Supporting documentation Algorithm 1 (PDF 471 KB)

Published:

22 January 2021
Supporting documentation Algorithm 2 (PDF 494 KB)

Published:

22 January 2021
Supporting documentation Algorithm 3 (PDF 505 KB)

Published:

22 January 2021
Draft guideline (PDF 848 KB)

Published:

22 January 2021
Equality impact assessment 3 (PDF 119 KB)

Published:

22 January 2021
Committee member list (PDF 137 KB)

Published:

22 January 2021
Evidence review A (PDF 2.71 MB)

Published:

22 January 2021
Evidence review B (PDF 917 KB)

Published:

22 January 2021
Evidence review C (PDF 1.57 MB)

Published:

22 January 2021
Evidence review D (PDF 1.58 MB)

Published:

22 January 2021
Evidence review E (PDF 1.84 MB)

Published:

22 January 2021
Evidence review F (PDF 3.57 MB)

Published:

22 January 2021
Evidence review G (PDF 2.23 MB)

Published:

22 January 2021
Evidence review H (PDF 5.45 MB)

Published:

22 January 2021
Evidence review I (PDF 1.81 MB)

Published:

22 January 2021
Evidence review J (PDF 967 KB)

Published:

22 January 2021
Evidence review K (PDF 2.31 MB)

Published:

22 January 2021
Evidence review L (PDF 17.98 MB)

Published:

22 January 2021
Evidence review M (PDF 2.26 MB)

Published:

22 January 2021
Comments form (MSWord 37 KB)

Published:

22 January 2021
Evidence review N (PDF 4.35 MB)

Published:

25 January 2021

Pre-consultation documents released

Economic plan (PDF 133 KB)

Published:

24 November 2020
Review questions (PDF 153 KB)

Published:

24 November 2020
Search strategies (PDF 642 KB)

Published:

24 November 2020

Scope published

Final scope (PDF 339 KB)

Published:

13 March 2019
Consultation comments and responses (PDF 1.13 MB)

Published:

13 March 2019
Equality impact assessment 2 (PDF 163 KB)

Published:

13 March 2019

Committee meetings

Committee meeting
Minutes 1 (PDF 204 KB)

Published:

18 March 2019
Minutes 2 (PDF 322 KB)

Published:

08 May 2019
Minutes 3 (PDF 194 KB)

Published:

21 June 2019
Minutes 4 (PDF 200 KB)

Published:

31 July 2019
Minutes 5 (PDF 260 KB)

Published:

19 September 2019
Minutes 6 (PDF 288 KB)

Published:

11 November 2019
Minutes 7 (PDF 286 KB)

Published:

30 January 2020
Minutes 8 (PDF 240 KB)

Published:

09 March 2020
Minutes 9 (PDF 215 KB)

Published:

25 August 2020
Minutes 10 (PDF 215 KB)

Published:

27 August 2020
Minutes 11 (PDF 256 KB)

Published:

09 September 2020
Minutes 12 (PDF 214 KB)

Published:

21 September 2020
Minutes 13 (PDF 218 KB)

Published:

23 September 2020
Minutes 14 (PDF 343 KB)

Published:

18 December 2023
Minutes 15 (PDF 273 KB)

Published:

18 December 2023
Minutes 16 (day 1) (PDF 274 KB)

Published:

18 December 2023
Minutes 16 (day 2) (PDF 223 KB)

Published:

18 December 2023
Minutes (PDF 274 KB)

Published:

09 January 2024

Draft scope consultation

Draft scope consultation
Draft scope (PDF 406 KB)

Published:

07 December 2018
Comments form (MSWord 31 KB)

Published:

07 December 2018
Equality impact assessment 1 (PDF 314 KB)

Published:

07 December 2018

Scoping workshop: London

Workshop notes (PDF 331 KB)

Published:

12 November 2018

Update on 24 November 2021

Declaration of interests
Register of interests (PDF 533 KB)

Published:

24 November 2021
Guidance published
Consultation comments and responses (PDF 1.34 MB)

Published:

24 November 2021
Committee member list (PDF 121 KB)

Published:

24 November 2021
Stakeholder list updated
Stakeholder list - Type 2 diabetes in adults (PDF 292 KB)

Published:

23 November 2021
Stakeholder list - Chronic kidney disease (PDF 199 KB)

Published:

23 November 2021
Draft guidance consultation
Draft guidance consultation
Equality impact assessment 3 (PDF 118 KB)

Published:

01 September 2021
Draft guideline (PDF 204 KB)

Published:

01 September 2021
Evidence review (PDF 3.88 MB)

Published:

01 September 2021
Comments form (MSWord 40 KB)

Published:

01 September 2021